We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study. |
Principal Investigator
Sukeshi Arora
Alicia Coderoni
(210) 450-1000
coderoni@uthscsa.edu
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
1. Patients with HCC who are not candidates for curative or locoregional treatments .
2. Patients who are candidates to receive first-line immunotherapy-based regimens (i.e., atezolizumab/bevacizumab)
3. ECOG performance status 0-2
4. Patients who will have baseline biopsy for HCC and background liver biopsy per SOC
1. Prior systemic therapy for HCC
2. Any contraindication to immunotherapy
a) Prior transplant
b) Uncontrolled autoimmune diseases (i.e., autoimmune hepatitis)
3. Prior anti-PD-L1, anti-PD1, or anti-CTLA4 antibody (or another checkpoint inhibitor)